Clinical Trial Update: The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the effects of JNJ-39393406 on psychometric performance and residual depressive symptoms completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• JNJ-39393406

Snippet

Sponsor: Tangent Data | Conditions: Depression | Phase 2 | Status: COMPLETED